贝利尤单抗在狼疮性肾炎患者中的安全性和有效性:BLISS-LN研究的开放标签扩展研究
本研究为BLISS-LN的28周开放标签扩展研究,评估贝利尤单抗在活动性狼疮性肾炎成人患者中的安全性和有效性。255例患者接受每月静脉贝利尤单抗10 mg/kg联合标准治疗,未发现新的安全性信号,疗效总体维持。
要点
- 255例接受治疗,245例(97%)完成研究
- 安慰剂转贝利尤单抗组不良事件62%、严重不良事件4%;贝利尤单抗转贝利尤单抗组分别为70%和8%
- 从开放标签基线至第28周,主要疗效肾脏应答和完全肾脏应答比例均升高
核心结论
- 未发现新的安全性信号,开放标签阶段疗效总体维持。
研究设计与样本
- BLISS-LN研究的28周开放标签扩展研究,纳入完成BLISS-LN的合格患者,每月静脉给予贝利尤单抗10 mg/kg联合标准治疗。
- 257例入组,255例接受治疗(安全性人群:安慰剂转贝利尤单抗组n=123,贝利尤单抗转贝利尤单抗组n=132),245例(97%)完成研究。
主要发现
- 不良事件和严重不良事件:安慰剂转贝利尤单抗组分别为62%和4%,贝利尤单抗转贝利尤单抗组分别为70%和8%;安慰剂转贝利尤单抗组发生1例死亡。
- 从开放标签基线至第28周,主要疗效肾脏应答比例升高:安慰剂转贝利尤单抗组从60%升至67%,贝利尤单抗转贝利尤单抗组从70%升至75%。
- 从开放标签基线至第28周,完全肾脏应答比例升高:安慰剂转贝利尤单抗组从36%升至48%,贝利尤单抗转贝利尤单抗组从48%升至62%。
- 基于双盲期标准的事后分析:主要疗效肾脏应答比例变化为安慰剂转贝利尤单抗组从54%降至53%、贝利尤单抗转贝利尤单抗组从66%降至52%;完全肾脏应答比例变化为安慰剂转贝利尤单抗组从34%升至35%、贝利尤单抗转贝利尤单抗组从46%降至41%。
- 贝利尤单抗转贝利尤单抗组应答率看似下降归因于因非SLE原因(而非肾炎)停药或使用糖皮质激素;开放标签基线与第28周的中位UPCR和eGFR值相似。
关键数值与推荐
- 主要疗效肾脏应答定义:UPCR≤0.7,eGFR不低于开放标签基线值20%以上或≥60 ml/min per 1.73 m2,未使用禁用药物。
- 完全肾脏应答定义:UPCR<0.5,eGFR不低于开放标签基线值10%以上或≥90 ml/min per 1.73 m2,未使用禁用药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed belimumab's safety and efficacy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Eligible patients completing BLISS-LN received monthly intravenous belimumab 10 mg/kg plus standard therapy. End points included safety, open-label week 28 primary efficacy renal response (urine protein-creatinine ratio [UPCR] ≤0.7, eGFR no more than 20% below open-label baseline value or ≥60 ml/min per 1.73 m2, no prohibited medications) and complete renal response (UPCR <0.5, eGFR no more than 10% below open-label baseline value or ≥90 ml/min per 1.73 m2, no prohibited medications), and UPCR and eGFR by visit. Responses were also analyzed post hoc using the double-blind phase criteria. RESULTS: Of 257 enrolled patients, 255 were treated (safety population: n=123 switched from placebo-to-belimumab; n=132 remained on belimumab); 245 (97%) patients completed the study. Adverse events and serious adverse events were experienced by 62% and 4% of placebo-to-belimumab patients, respectively, and by 70% and 8% of belimumab-to-belimumab patients, respectively. One death occurred in the placebo-to-belimumab group. From open-label baseline to week 28, increases occurred in the proportions of patients achieving primary efficacy renal response (placebo-to-belimumab: from 60% to 67%; belimumab-to-belimumab: from 70% to 75%) and complete renal response (placebo-to-belimumab: from 36% to 48%; belimumab-to-belimumab: from 48% to 62%). Based on double-blind phase criteria, changes also occurred in the proportions achieving primary efficacy renal response (placebo-to-belimumab: from 54% to 53%; belimumab-to-belimumab: from 66% to 52%) and complete renal response (placebo-to-belimumab: from 34% to 35%; belimumab-to-belimumab: from 46% to 41%). The seeming decrease in response rates in the belimumab-to-belimumab groups was attributed to discontinuations/administration of glucocorticoids for non-SLE reasons as opposed to nephritis. Median UPCR and eGFR values were similar at open-label baseline and week 28. CONCLUSIONS: No new safety signals were identified, and efficacy was generally maintained throughout the open-label phase. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: BLISS-LN, NCT01639339.
引用
- Furie R, Rovin BH, Houssiau F, et al. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Clin J Am Soc Nephrol. 2022. PMID: 36302567. doi:10.2215/CJN.02520322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。